Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBIT Margin (2018 - 2025)

Historic EBIT Margin for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 27.62%.

  • BioNexus Gene Lab's EBIT Margin rose 232400.0% to 27.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.81%, marking a year-over-year decrease of 151000.0%. This contributed to the annual value of 16.55% for FY2024, which is 100000.0% up from last year.
  • BioNexus Gene Lab's EBIT Margin amounted to 27.62% in Q3 2025, which was up 232400.0% from 27.05% recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's EBIT Margin registered a high of 13.13% during Q2 2024, and its lowest value of 99.01% during Q3 2023.
  • In the last 5 years, BioNexus Gene Lab's EBIT Margin had a median value of 3.32% in 2024 and averaged 11.67%.
  • In the last 5 years, BioNexus Gene Lab's EBIT Margin crashed by -964800bps in 2023 and then skyrocketed by 481600bps in 2024.
  • BioNexus Gene Lab's EBIT Margin (Quarter) stood at 6.2% in 2021, then crashed by -170bps to 4.32% in 2022, then surged by 362bps to 11.34% in 2023, then crashed by -245bps to 16.49% in 2024, then crashed by -67bps to 27.62% in 2025.
  • Its EBIT Margin stands at 27.62% for Q3 2025, versus 27.05% for Q2 2025 and 28.94% for Q1 2025.